Oregovomab

Oregovomab
Monoclonal antibody
Type	Whole antibody
Source	Mouse
Target	CA125
Clinical data
Trade names	OvaRex
ATC code	none;
Identifiers
CAS Number	213327-37-8 ;
ChemSpider	none;
UNII	HX101E7L6S;
KEGG	D05269 ;
Chemical and physical data
Molar mass	ca. 150 kg/mol
	(what is this?) (verify)

Oregovomab (marketed under the trade name OvaRex) is a mouse monoclonal antibody it binds to the antigen CA125, a carbohydrate antigen. It is designed for the treatment of ovarian cancer.^[1]^[2]

This drug was developed by AltaRex Corp.

References

↑ "Statement on a Nonproprietary Name Adopted by the USAN Council - Oregovomab". American Medical Association. Archived from the original on 14 August 2003. Retrieved 25 October 2008.
↑ Pietragalla A, Duranti S, Daniele G, Nero C, Ciccarone F, Lorusso D, et al. (February 2021). "Oregovomab: an investigational agent for the treatment of advanced ovarian cancer". Expert Opinion on Investigational Drugs. 30 (2): 103–110. doi:10.1080/13543784.2021.1868436. PMID 33423551.

[1] "Statement on a Nonproprietary Name Adopted by the USAN Council - Oregovomab". American Medical Association. Archived from the original on 14 August 2003. Retrieved 25 October 2008.

[Pietragalla_2021-2] Pietragalla A, Duranti S, Daniele G, Nero C, Ciccarone F, Lorusso D, et al. (February 2021). "Oregovomab: an investigational agent for the treatment of advanced ovarian cancer". Expert Opinion on Investigational Drugs. 30 (2): 103–110. doi:10.1080/13543784.2021.1868436. PMID 33423551.

[1]

[2]